Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) — by way of NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare know-how firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians establish the situation of continual low again ache, introduced at the moment that Dr. Christopher Ames, Director of Spinal Deformity and Backbone Tumor Surgical procedure and Co-Director of the Mixed Excessive Threat Backbone Service, the Neurospinal Problems Program, and the us Backbone Middle on the College of California at San Francisco will advise the corporate as a Key Opinion Chief (KOL) nationally.
Persistent low again ache (cLBP) is a main reason behind opioid dependancy within the U.S. and the one costliest analysis in the USA. Aclarion’s Nociscan resolution is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to spotlight if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers essential insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods.
Dr. Ames is becoming a member of the hassle to deliver better readability to the analysis of continual low again ache by the Aclarion KOL program. “Diagnosing ache has been a conundrum within the therapy of spinal issues for many years. A choice assist software like Nociscan can be an vital addition to higher understanding spinal issues and will improve physicians’ analysis, which is able to straight impression affected person outcomes,” acknowledged Dr. Ames. “Leveraging improvements like Nociscan to objectively measure ache biomarkers is a dramatic step ahead within the evolution of understanding and treating continual low again ache.”
“Aclarion is advancing the intersection between knowledge and healthcare addressing the expensive disabling situation of continual low again ache (cLBP). Dr. Ames is without doubt one of the foremost thinkers translating knowledge pushed purposes to actual affected person care,” stated Brent Ness, CEO of Aclarion. “We’re thrilled to have him on our KOL workforce and stay up for his many contributions that we count on will drastically enhance Nociscan and its scientific utility.”
Along with beforehand printed scientific proof, Aclarion just lately introduced inclusion of Nociscan within the pivotal Nationwide Institutes of Health funded trial, Biomarkers for the Analysis of Backbone Remedies, which is able to embody 200 sufferers throughout seven main tutorial educating establishments in the USA. Additionally, in December 2022, Aclarion introduced the addition of a brand new patent to deal with anaerobic micro organism that may seed into the intervertebral disc, proliferate, and speed up painful disc degeneration. Collectively, these prior and present initiatives illustrate the significance of Aclarion’s disruptive innovation to the spine business.
About Aclarion, Inc.
Aclarion is a healthcare know-how firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize scientific therapies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers essential insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods. For extra data, please go to www.aclarion.com.
Ahead Trying Statements
This press launch comprises forward-looking statements inside the which means of the Personal Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Alternate Act of 1934 in regards to the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic details, similar to “anticipates,” “believes” and “expects” or comparable expressions, are forward-looking statements. These forward-looking statements are based mostly on the present plans and expectations of administration and are topic to various uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra totally in our filings with the Securities and Alternate Fee. Readers are inspired to evaluation the part titled “Threat Components” within the Firm’s Prospectus dated April 21, 2022, as filed with the Securities and Alternate Fee on April 25, 2022 below Rule 424(b)(4), in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Alternate Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not because of new data, future occasions or in any other case.
Kirin M. Smith
PCG Advisory, Inc.